Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.65 |
| ▸ | ABL1 | P00519 | 7/20 | 0.46 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | LYN | P07948 | 4/20 | 0.44 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | YES1 | P07947 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.44 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41603 | 0.83 | SRC (0.63) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL41010 | 0.83 | SRC (0.49) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL42448 | 0.83 | SRC (0.48) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL41600 | 0.79 | SRC (0.44) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL4278670 | 0.79 | SRC (1.00) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL41148 | 0.73 | JAK2 (0.41) | SRCBTKJAK2FGFR1FGFR2 | |
| SCHEMBL40821 | 0.72 | SRC (0.49) | SRCABL1LCKEPHB6YES1 | |
| SCHEMBL14936723 | 0.72 | SRC (0.39) | SRCDYRK3HTR1AADRA1A | |
| SCHEMBL41177 | 0.72 | LRRK2 (0.46) | SRCABL1PIK3CDJAK2PDGFRB | |
| SCHEMBL15095306 | 0.71 | SRC (0.87) | SRCABL1LCKEPHB6YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | claimed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | claimed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | claimed |
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | SRC 401/4885ABL1 181/4885KIT 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.